Dr. Saba Radhi, MD

Dr. Radhi practices at City of Hope Cancer Center Phoenix in Goodyear, Arizona, part of City of Hope.

Dr. Radhi's NPI, 1851583751, was assigned on August 14, 2007. Dr. Radhi holds Arizona license 54845.

Dr. Radhi's primary practice is City of Hope Cancer Center Phoenix, at 14200 West Celebrate Life Way, Goodyear, AZ 85338 in Maricopa County. The practice phone is (623) 207-3000.

Dr. Radhi's primary practice is City of Hope Cancer Center Phoenix in Goodyear, Arizona, part of City of Hope. Dr. Radhi is also affiliated with Banner Gateway Medical Center. The medical group on file is City of Hope. Dmand AI also links Dr. Radhi to 2 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Radhi practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Radhi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Radhi's licenses on file in 2 states: Arizona and Texas.

CMS data shows 329 Medicare services from Dr. Radhi across 3 procedure codes in 2024, all of them office visits, for 105 Medicare patients. Medicare paid $31,870 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 105 Medicare patients who saw Dr. Radhi in 2024. The largest group is 75 to 84, with 53 patients. 75% of them have high blood pressure, and 73% have high cholesterol. Their average risk score is 2.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Radhi's median patient age at 71, with 45% women.

In 2024, Dr. Radhi wrote 444 Medicare Part D claims for 111 patients. 74% of them were for generic drugs. CMS names the drug for 286 of them, across 11 drugs with 11 or more claims each, at $1,079,122 in total drug cost. In 2022, CMS named 29 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Radhi for performance year 2024, reported as part of a group. Dr. Radhi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Radhi as offering telehealth.

Dmand AI links 8 papers to Dr. Radhi, published from 2011 to 2014. 2011 was the busiest year, with 3. Dr. Radhi's most frequent co-authors are Kenneth Michael Nugent, MD, Jose A. Figueroa, MD and Apurva Pandey, MD.

Dmand AI links Dr. Radhi to 8 clinical trials, 6 of them phase 3 studies. 7 are still active or recruiting. Conditions studied include Anal Canal Carcinoma, Carcinoma, Intraductal, Noninfiltrating and Cystadenocarcinoma, Mucinous. National Cancer Institute (NCI) sponsors the most, 6.

CMS Open Payments shows 176 general payments to Dr. Radhi from 34 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 72% of the total. Pfizer Inc. paid the most, $1,430.